MUMBAI Feb 10 Indian drugmaker Aurobindo Pharma
said on Friday it was looking to set up a
manufacturing facility for injectable products in the United
States, days after President Donald Trump called on
pharmaceutical companies to make more drugs locally.
Trump urged U.S. drug industry executives in a meeting last
month to make more drugs locally, and lower drug prices. He has
also proposed to impose a penalty in the form of a 'border tax'
on U.S. imports, a move heavily criticised by several
Aurobindo, India's fourth-largest drugmaker by sales, gets
more than half its total revenue from selling everything from
HIV/AIDS and anti-bacterials to asthma and schizophrenia drugs
in the United States.
The company has the bandwidth to add manufacturing in the
United States "if there is an increased emphasis on that", its
U.S. business chief, Bob Cunard, said in an earnings briefing.
"We don't have any current injectable manufacturing in the
U.S., but we do have plans for construction and build out of a
sterile injectables facility at our East Windsor (New Jersey)
campus," Cunard said.
At its current New Jersey facility, Aurobindo's only plant
in the United States, the company makes non-penicillin and
non-cephalosporin products, according to its website. The bulk
of its U.S. supply still comes from India, where it has six
Aurobindo reported a lower-than-expected October-December
profit on Friday, hurt by price erosion in the United States.
India's drug industry is worth about $15 billion and
supplies roughly 30 percent of the medicines sold in the United
States. It is, however, now facing increasing uncertainty as
Trump talks about changes to healthcare policy and stresses on
job creation in the United States.
(Reporting by Zeba Siddiqui in Mumbai; Editing by Himani